CGCI initiated the Non-Hodgkin Lymphoma Project to elucidate the mutation spectrums of the two most abundant forms of non-Hodgkin lymphoma (NHL)Opens in a New Tab: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Though previous research uncovered some genetic abnormalities in FL and DLBCL, more extensive genome-wide analysis is needed to fully understand the biology of these two cancers.
NHL originates from the white blood cells of the immune system and is a common malignancy among North American adults. FL is an indolent (slow-growing) disease that derives exclusively from germinal center B-cells. A subset of FL transition into DLBCL, and the cause is yet unknown. Unlike FL, DLBCL is a fast-growing cancer that derives from either germinal center B-cells or activated B-cells.
By applying the most advanced sequencing analysis, CGCI researchers revealed frequent novel mutations in the chromatin modification pathway in subsets of NHL. Chromatin modification, which regulates gene expression, had not been previously implicated in NHL pathogenesis. Researchers are testing the functional significance of these chromatin modifying genes in driving the initiation and progression of NHL. Understanding the role of chromatin modification in NHL subpopulations may lead to better treatments for patients.
The NHL Project has completed all phases of the timeline.
Visit the CGCI Overview page to learn more about the general timeline of CGCI projects.